Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Empagliflozin on Hepatic Glucose Metabolism
NCT03193684Phase 4Completed
- Sponsor
- UT Health San Antonio
- Start
- May 2018
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Empagliflozin with Placebo (2 arms). Primary endpoint: Effect of Empagliflozin on Autonomic Nervous System at 12 weeks. Started May 2018; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03193684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03193684.